NDC 69677-071 Mas Care-pak Dexamethasone

The NDC code 69677-071 is assigned by the FDA to the product Mas Care-pak Dexamethasone which is product labeled by Mas Management Group Inc.. The product's dosage form is . The product is distributed in a single package with assigned NDC code 69677-071-02 1 kit in 1 box * .9 ml in 1 packet (67777-130-02) * .55 ml in 1 pouch (67777-121-14) * 1 ml in 1 vial (63323-506-01). This page includes all the important details about this product, including active and inactive ingredients, pharmagologic classes, product uses and characteristics, UNII information and RxNorm crosswalk.

By intravenous or intramuscular injection when oral therapy is not feasible:Endocrine Disorders​Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance).Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used).Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful.Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected.Congenital adrenal hyperplasiaNonsuppurative thyroiditisHypercalcemia associated with cancer2. Rheumatic DisordersAs adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:Post-traumatic osteoarthritisSynovitis of osteoarthritisRheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).Acute and subacute bursitisEpicondylitisAcute nonspecific tenosynovitisAcute gouty arthritisPsoriatic arthritisAnkylosing spondylitis3. Collagen DiseasesDuring an exacerbation or as maintenance therapy in selected cases of:Systemic lupus erythematosusAcute rheumatic carditis4. Dermatologic DiseasesPemphigusSevere erythema multiforme (Stevens-Johnson syndrome)Exfoliative dermatitisBullous dermatitis herpetiformisSevere seborrheic dermatitisSevere psoriasisMycosis fungoides5. Allergic StatesControl of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in:Bronchial asthmaContact dermatitisAtopic dermatitisSerum sicknessSeasonal or perennial allergic rhinitisDrug hypersensitivity reactionsUrticarial transfusion reactionsAcute noninfectious laryngeal edema (epinephrine is the drug of first choice).6. Ophthalmic DiseasesSevere acute and chronic allergic and inflammatory processes involving the eye, such as:Herpes zoster ophthalmicusIritis, iridocyclitisChorioretinitisDiffuse posterior uveitis and choroiditisOptic neuritisSympathetic ophthalmiaAnterior segment inflammationAllergic conjunctivitisKeratitisAllergic corneal marginal ulcers7. Gastrointestinal DiseasesTo tide the patient over a critical period of the disease in:Ulcerative colitis (systemic therapy)Regional enteritis (systemic therapy)8. Respiratory DiseasesSymptomatic sarcoidosisBerylliosisFulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy.Loeffler’s syndrome not manageable by other means.Aspiration pneumonitis9. Hematologic DisordersAcquired (autoimmune) hemolytic anemia.Idiopathic thrombocytopenic purpura in adults(IV only; IM administration is contraindicated).Secondary thrombocytopenia in adultsErythroblastopenia (RBC anemia)Congenital (erythroid) hypoplastic anemia10. Neoplastic DiseasesFor palliative management of:Leukemias and lymphomas in adultsAcute leukemia of childhood11. Edematous StatesTo induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.12. MiscellaneousTuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.Trichinosis with neurologic or myocardial involvement.13. Diagnostic testing of adrenocortical hyperfunction.14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. Stop use and ask a doctor if:Irritation or redness developscondition persists for more than 72 hoursCleansing of an injection site

RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:

• RxCUI: 1812079 - dexAMETHasone sodium phosphate 10 MG in 1 ML Injection
• RxCUI: 1812079 - 1 ML dexamethasone phosphate 10 MG/ML Injection
• RxCUI: 1812079 - dexamethasone phosphate 10 MG (as dexamethasone sodium phosphate 11 MG) per 1 ML Injection
• RxCUI: 797544 - isopropyl alcohol 70 % Medicated Pad
• RxCUI: 797544 - isopropyl alcohol 0.7 ML/ML Medicated Pad